Drugs / Hexavalent vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03402776 | May 2018 → May 2020 | disease related to hematopoietic stem cell transplant | University Hospital, Grenoble | Unknown | No outcome recorded |
| Phase 3 | NCT01839175 | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06748612 | Jan 2025 → Dec 2027 expected | poliomyelitis | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06879327 Background | May 2025 → Sep 2027 expected | malaria | PATH | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hexavalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879327 ↗ |
| Known as | wP-Hexa | “Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus...” NCT06748612 ↗ |
| Modality | Vaccine | “DTaP-IPV-HB-PRP-T is a hexavalent vaccine” PMID 30471953 ↗ Nov 2018 |
| Route | Intramuscular | “0.5 mL intramuscular injection at 2, 3 and 4 months of age” NCT01839175 ↗ |